Lilly Enlists Boehringer for Duloxetine

A $280 million deal with Eli Lilly for duloxetine allows Boehringer Ingelheim to expand its presence in both urology and CNS--thanks to Lilly's deluge of near-market therapeutics, which has required the firm for the first time to enter a significant co-promotion deal for one of its own important products.

When Boehringer Ingelheim GMBH in-licensed the prostatic hyperplasia treatment tamsulosin (Flomax) from Astellas Pharma Inc. in 1994 [See Deal], the private German company had zero experience in urology. Boehringer, in fact, at first underestimated Flomax's potential, and initial sales reflected this limited faith: the drug that has become the company's strongest seller, with €613 million ($629 million) in 2001 sales, started off slowly.

Boehringer's December 2002 co-promotion deal for duloxetine with Eli Lilly & Co.[See Deal], while expanding its presence in...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo